How do you start an optometry practice in 2027?

Direct Answer

×

CRO SYNDICATE

SPONSORED

Kory WhiteFractional CRO · 25 yrs · $0→$200M

Hire a Fractional CRO

Need a fractional Chief Revenue Officer?

Chief Revenue OfficerRevenue LeaderVP of SalesSales Leader

CRO Syndicate connects you with vetted fractional & interim revenue leaders — nationwide and across Maryland & DC.

Book a Call →

Kory White LinkedIn →CRO Syndicate →

Starting an optometry practice in 2027 — a state-licensed eyecare clinic providing comprehensive eye exams + vision correction (spectacles + contact lenses) + ocular disease diagnosis and treatment + myopia management + dry eye disease + specialty contact lens fitting — means choosing among five business models against a fast-consolidating chain market, then nailing the capital + equipment + payer + optical-capture quartet. The five models: (1) solo-OD independent (~75% of independent ODs per AOA Annual Practice Survey, 2-3 lanes, 1,800-3,500 sq ft, $550K-$1.2M gross, 22-35% net = $135K-$420K owner-OD); (2) multi-OD group (2-4 ODs, 4-8 lanes, $1.5M-$5M gross, 18-30% net); (3) affiliate-network independent (Vision Source ~3,000+ ODs at $750/mo led by Steven Eiss + Essilor-owned since 2015 / IDOC ~500 practices at ~$1,200/mo led by Dave Brown / PECAA ~1,500+ aligned ODs); (4) corporate-affiliated — sublease at LensCrafters or Pearle Vision OR W-2 employed at MyEyeDr (KKR-backed, Sue Downes CEO, ~860 offices) / National Vision NASDAQ:EYE (Reade Fahs CEO, ~1,400 stores including America's Best ~900 + Eyeglass World ~125) / Walmart Vision ~3,000+ sublease / Costco Optical ~580+ at $130-$180K base; (5) IDSO-equivalent partial-recap (EyeCare Partners Partners Group+FFL ~700+ / EyeSouth Partners Shore Capital ~300+ / Keplr Vision Greenbriar Equity ~110+ / US Eye Kuvera+Aldine ~75+ / Vision Innovation Partners Centre Lane ~80+ / Spectrum Vision Partners), selling 60-80% at 5-8x EBITDA vs traditional 0.65-0.85x collections. The chain threat is real: EssilorLuxottica NYSE:EL (Chairman Francesco Milleri + CEO Andrea Guerra) owns LensCrafters ~840 + Pearle ~500 + Target Optical ~500 + Sunglass Hut ~3,200 + EyeMed ~70M covered lives + Essilor lens manufacturing, Warby Parker NASDAQ:WRBY (Neil Blumenthal + Dave Gilboa ~270 stores), and chain share rose from ~15% in 2010 to ~30%+ in 2024 toward 40%+ by 2030 per Review of Optometric Business. Capital — $350K-$800K cold-start 2-3 lane OR $600K-$1.5M acquisition at 60-80% of trailing 12-mo collections — funded via SBA 7(a) through Live Oak Bank Eyecare, Bank of America Practice Solutions, First Citizens Practice Solutions, Provide.com (was Lendeavor), Huntington Practice Finance, or US Bank Practice Finance. Exam-lane equipment fundamentals at $15-$25K/lane: Marco TRS-3100/5100/6100 chair-stand + Reichert Ultramatic phoropter $4-$18K + Haag-Streit BQ-900 slit lamp gold $4-$15K + Nidek/Topcon auto-refractor $7-$15K + NCT $3-$8K. Diagnostic imaging (the medical-OD enablers): Canon CR-2 retinal camera $25-$40K OR Optos California ultra-widefield 200° $90-$130K + Heidelberg Spectralis OCT $60-$80K gold standard OR Topcon Maestro2 / Zeiss Cirrus 6000 + corneal topographer Medmont E300 / Eaglet ESP / Oculus Pentacam $25-$45K + HFA3 visual field $22-$30K + Zeiss IOLMaster 700 axial length biometer $55-$70K (CRITICAL for myopia management). Optical lab: Essilor Independent Labs (Varilux + Crizal + Transitions + Stellest myopia) + Walman Optical employee-owned + Hoya Vision (MiYOSMART myopia + Recharge AR) + Younger Optics (Drivewear + NuPolar) + Shamir Insight (Autograph III + Glacier+ AR). PMS at $300-$1,500/mo: Compulink Advantage + RevolutionEHR cloud OD-specific fastest-growing + Crystal PM + Eyefinity OfficeMate (VSP-owned, deep VSP integration) + Maximeyes / Acuity Logic / Uprise. Operations: hiring associate OD $130-$170K + opticians $22-$35/hr + techs $18-$26/hr; vision insurance vs medical billing workflow (VSP ~80M Michael Guyette CEO + ~30% US vision insurance share / EyeMed ~70M Lukas Ruecker CEO EssilorLuxottica-owned / Spectera ~25M UHG / Davis Vision/MetLife ~20M / Versant Health Superior+Davis) compresses optical margin 40-60%, vs medical-OD 99213-99215 ($75-$170) + 92133 RNFL $45 + 92134 macular $45 + 92250 fundus $50 + G0117 diabetic $53 at 2-3x reimbursement. The S-T-O-P optical sale workflow (Select frame → Talk lens tech → Offer treatments AR/blue/photochromic → Position pricing) drives the top-vs-bottom delta — top quartile closes 70-85%, bottom 35-45%. Contact lens annual supply 75-90% conversion: Acuvue Oasys 1-Day HydraLuxe (Johnson & Johnson Vision) / Alcon DAILIES TOTAL1 + Precision1 + Air Optix HydraGlyde / CooperVision MyDay + Biofinity / Bausch + Lomb Biotrue ONEday + INFUSE + Ultra. The four 2027 revenue moats independents counter chains with: (A) myopia management $4-$6B emerging specialty 25-40%/yr — CooperVision MiSight 1-day FDA + Essilor Stellest CE-mark + Hoya MiYOSMART + Visioneering NaturalVue Multifocal + Paragon CRT/Wave/Euclid ortho-k + atropine 0.05% compounded via Imprimis/Leiter's at $1,500-$3,500/yr/pediatric packages; (B) dry eye disease center $300-$3,000 protocols outside vision insurance — TearLab osmolarity + Lumenis OptiLight M22 IPL $75-$110K FDA + J&J LipiFlow + NULIDS + Restasis (AbbVie) / Cequa (Sun Pharma) / Xiidra / Tyrvaya (Viatris) / Miebo (Bausch + Lomb); (C) specialty contact lens — sclerals $1,200-$3,500 (BostonSight / Valley Contax / X-Cel Specialty / Visionary Optics) + ortho-k $1,500-$3,500; (D) medical-OD transition away from vision-plan reliance toward 99213-99215 medical CPT billing. Compliance non-negotiables: state OD board + DEA + state therapeutic/laser (TPA scope varies; OK+LA+KY+AK+VA grant laser SLT/YAG/LPI) + NPI + HIPAA + OSHA Bloodborne Pathogens + FTC Eyeglass Rule (Rx released after refraction no charge) + FTC Contact Lens Rule (CL Rx + 1-yr verification) + state optician licensure (~22 states). AI imaging FDA-cleared add-ons $300-$2,000/mo: Eyenuk EyeArt diabetic retinopathy + Notal Vision ForeseeHome AMD + RetinAI multi-pathology OCT + AEYE Health autonomous DR. The hardest part is NOT capital or OCT/topographer spend — it is the trifecta of (1) optical capture via S-T-O-P (55-70% of independent OD gross), (2) VSP/EyeMed write-off management + medical-OD billing transition, and (3) chain/corporate positioning via myopia + dry eye + specialty CL + medical-OD moats. Benchmark sources: American Optometric Association (AOA), Review of Optometric Business, Vision Council, BLS Occupational Outlook 2024 — Optometrists, ASCO, ARBO, NBEO, American Academy of Optometry, Brien Holden Vision Institute, and International Myopia Institute for the myopia management consensus that grounds the $4-$6B emerging-specialty thesis.

Table of Contents

Part 1 -- Foundations

• Market size, OD supply, optical retail market
• Four practice archetypes
• OD pathway, NBEO, TPA scope
• Chain consolidation + medical-OD shift

Part 2 -- Build-Out & Capital

• Real estate + exam lane build-out
• Exam-lane equipment + diagnostic imaging
• Optical lab + frame inventory
• PMS + AI imaging + supplies
• SBA + eyecare-specific financing

Part 3 -- Operations

• Hiring (associate OD + opticians + techs)
• Vision insurance vs medical billing workflow
• S-T-O-P optical sale workflow
• Contact lens + specialty CL revenue
• Myopia management revenue lever
• Dry eye disease center model
• Compliance: HIPAA + OSHA + FTC + optician licensure

Part 4 -- Growth & Exit

• Marketing realities
• Scale model + IDSO-equivalent market
• Vision Source/IDOC/PECAA affiliate routes
• Exit options
• Chain threat + independent moats

---

PART 1 -- FOUNDATIONS

1. Market size, OD supply & the optical retail market

US optical retail generates ~$50B annual revenue (Vision Council 2024) -- spectacle lenses ~$22B + frames ~$15B + contact lenses ~$8B + sunwear ~$5B -- across ~40K independent optometry practices + ~9,000 chain/corporate locations + ~46K active ODs (AOA + BLS 2024). The defining 2024-2027 macro: chain consolidation accelerating (chain ODs grew from ~15% in 2010 to ~30%+ in 2024 per Review of Optometric Business, projected 40%+ by 2030) + the myopia management revolution (FDA approval of CooperVision MiSight 1-day 2019 + Essilor Stellest CE-mark + ortho-k mainstreaming + atropine 0.05% compounded).

> ### Quick Facts > - ~$50B US optical retail (Vision Council 2024) > - ~46K active optometrists (AOA + BLS 2024) > - ~40K independent optometry practices > - ~9,000 chain/corporate eyecare locations > - ~75% of independent ODs in solo or 2-doc (AOA, trending corporate) > - ~$650-$900K avg solo OD gross collections > - $135-$220K owner-OD net (top quartile $280-$450K) > - VSP ~80M / EyeMed ~70M / Spectera ~25M / Davis ~20M covered lives > - ~30% chain market share 2024, 40%+ projected 2030

The chain market. EssilorLuxottica (Francesco Milleri Chairman, Andrea Guerra CEO) owns LensCrafters ~840 + Pearle Vision ~500 + Target Optical ~500 + Sunglass Hut ~3,200 = ~$5B+ US optical retail + EyeMed (~70M covered lives) + Essilor lens manufacturing + Ray-Ban/Oakley/Persol/Oliver Peoples frame brands. National Vision (NASDAQ:EYE, Reade Fahs CEO, ~1,400 stores) operates America's Best Contacts & Eyeglasses ~900 + Eyeglass World ~125 + Walmart Vision sublease + Fred Meyer Optical. MyEyeDr (KKR-backed since 2019, Sue Downes CEO, ~860 offices) -- fastest-growing roll-up of independent practices. Walmart Vision Centers ~3,000+ stores sublease ODs. Costco Optical ~580+ employed ODs $130-$180K. Warby Parker (NASDAQ:WRBY, Neil Blumenthal + Dave Gilboa, ~270 stores + ecommerce).

Vision Source / IDOC / PECAA. Vision Source (Steven Eiss former CEO, Essilor-owned since 2015) -- ~3,000+ affiliated ODs, $750/mo + buying-group rebates + consulting. IDOC (Dave Brown CEO, ~500 practices) -- heavier consulting + financial benchmarking + ~$1,200/mo. PECAA -- ~1,500+ aligned ODs, buying group + insurance leverage.

Education-debt + DSO-acceptance flywheel. OD-school debt averages $185K-$305K at graduation per ASCO 2024. New grads accept MyEyeDr/National Vision/Walmart/Costco employment at $130K-$170K starting + bonus because immediate cashflow services debt -- driving chain market share from ~15% in 2010 to ~30% in 2024 to projected 40%+ by 2030.

Demand fundamentals + myopia surge. 65+ population: ~58M in 2024 -> ~78M by 2035 (US Census), creating chronic-disease OD opportunity. Childhood myopia prevalence: ~25% in US 2024, projected ~50% by 2050 globally per Brien Holden Vision Institute -- driving the $4-$6B emerging myopia management specialty.

2. Four practice archetypes

The single most consequential 2027 decision is archetype selection -- it dictates capital intensity, payer mix, exit multiple, lifestyle.

Solo-OD independent. 1 owner-OD + 1-2 opticians + 1-2 techs + 1 front office. 2-3 lanes, 1,800-3,500 sq ft, $550K-$1.2M gross, 22-35% net = $135K-$420K. Most exposed to chain competition + VSP/EyeMed compression. Top quartile $1.2M-$2.5M with strong S-T-O-P + medical-OD billing + myopia buildout.

Multi-OD group. 2-4 ODs + 3-5 opticians + 3-5 techs + 2-3 front office. 4-8 lanes, 3,500-7,000 sq ft, $1.5M-$5M, 18-30% net = $270K-$1.5M. Operating leverage from shared optical + diagnostic equipment + insurance contracts. Common path to IDSO-equivalent.

Affiliate-network independent. Preserves branding + clinical autonomy + ownership + adds Vision Source ($750/mo)/IDOC ($1,200/mo)/PECAA buying-group rebates (Essilor lens 8-15% + frame co-op + CL manufacturer rebates) + practice consulting + insurance contract leverage.

Corporate-affiliated / employed. (a) Sublease at LensCrafters/Pearle/Target -- OD pays $3-$8K/mo rent + collects exam fees + production bonus; host owns optical. (b) Employed at MyEyeDr/National Vision/Walmart/Costco -- W-2 at $130-$180K base + bonus + benefits + zero ownership risk. Best for new-grads servicing OD school debt.

3. OD pathway, NBEO, state licensure & TPA scope

Clinical pathway: 4-yr undergraduate + OAT + 4-yr optometry school at one of ~23 ACOE-accredited schools (Berkeley, SUNY College of Optometry, UAB, Indiana, Houston, Ohio State, Pacific U, Salus, Illinois College, MBKU, Nova Southeastern, NEOMED, etc.) earning OD. Then NBEO Part I + Part II + Part III. Then state board license + jurisprudence. Many ODs add a 1-yr residency in ocular disease / cornea / pediatrics / low vision.

DEA registration for therapeutic/oral prescribing (oral antibiotics, oral steroids, oral antivirals). NPI for insurance billing. Medicaid optional.

TPA scope varies dramatically. All 50 states grant some therapeutic authority but scope varies -- Oklahoma + Louisiana + Kentucky + Alaska + Virginia grant the broadest including laser procedures (YAG capsulotomy, SLT, LPI). Most states grant topical + oral medication but reserve injections + laser to ophthalmology. CA + MA + NY + TX more restrictive. Check state board scope-of-practice -- drives chronic-disease billing potential.

Continuing Education. State boards require 18-50 CE hours per renewal cycle, 50%+ COPE-accredited. Major providers: AOA Optometry's Meeting, Vision Expo East NYC March + West Vegas September, SECO Atlanta March, AAO Academy, Review of Optometry CE Online.

4. Chain consolidation reality & the medical-OD shift

EssilorLuxottica owns ~$5B+ US optical retail + EyeMed (~70M lives, captive vision-insurance arm) + Essilor lens manufacturing + most major frame brands. MyEyeDr (KKR, ~860 offices) -- the fastest-growing roll-up; typically buys 60-80% equity + retains OD as clinical lead + retains branding initially + converts over 2-5 yrs + centralizes back-office. National Vision (NASDAQ:EYE, ~1,400 stores) -- low-cost model exam + 2 pairs $79.95.

The IDSO-equivalent in eyecare -- fastest-growing 2024-2027. Vision Innovation Partners (Centre Lane Partners) -- preserves practice branding + clinical autonomy + employees while centralizing insurance contracting, HR, marketing, supply. US Eye (Kuvera + Aldine Capital, ~75+) -- OD + MD combined. EyeCare Partners (Partners Group + FFL Partners, ~700+ locations) -- largest combined OD + MD platform. Keplr Vision (Greenbriar Equity, ~110+) -- independent-friendly retaining branding. EyeSouth Partners (Shore Capital, ~300+, ophthalmology-heavy). Spectrum Vision Partners (PE-backed Northeast). Typical deal: 60-80% equity at 5-8x EBITDA + clinical autonomy + 20-40% retained equity + second-bite at next recap in 3-7 years (2-3x return on retained).

The medical-OD shift -- the strategic moat. Independent ODs increasingly bill medical insurance (BCBS/Aetna/Cigna/UHC/Medicare) at 2-3x vision-plan reimbursement by managing chronic ocular disease: diabetic eye exam G0117 ($53 Medicare) + glaucoma 92083 visual field + 92250 fundus photography + dry eye + neuro-optometry post-concussion + neurolens prism. A patient w/ "red eye, headaches, floaters, blur with diabetes" bills medical 99213-99215 ($75-$170) + ancillary tests, NOT vision 92002/92004/92012/92014 ($45-$95). Heavy-medical practices net 35-50% vs heavy-vision-plan 18-28%.

---

PART 2 -- BUILD-OUT & CAPITAL

1. Real estate & exam lane build-out

> ### Quick Facts > - 2-lane startup: $250-$500K (1,200-2,000 sq ft) > - 3-lane independent: $350-$800K (1,800-3,500 sq ft) > - 4-lane full-diagnostic: $700K-$1.5M (3,000-5,000 sq ft) > - Acquisition: $600K-$1.5M at 60-80% trailing 12-mo collections > - TI build-out: $200-$350/sq ft > - Exam-lane equipment: $35-$75K per lane > - Frame inventory opening: $30-$80K (300-800 frames at 3x markup)

Site selection. Want 2-3 mile residential density 25K+ households + median HHI $60K+ + visible signage + 15-25 parking spots + co-tenant traffic (grocery/pharmacy/pediatric). Demographic match to focus: myopia mgmt near schools/young families, dry eye + medical-OD near 45+ retirees. Avoid heavy chain saturation -- if LensCrafters + America's Best + MyEyeDr + Walmart Vision within 2 miles, exam capture 2-3x harder.

Exam lane layout & MEP. OD build-out runs $200-$350/sq ft TI -- medical-grade plumbing at exam lanes + medical-grade electrical (chair-stand 20A dedicated) + HIPAA-compliant front office + ADA-accessible lanes + pre-test room with auto-refractor + NCT + retinal camera + dilation/wait area + optical retail floor + CL dispensing + optional lab room.

Build-out timeline runs 6-10 months lease-to-first-patient: 30-60 day design + permitting + 90-120 day construction + 30-60 day equipment install + insurance credentialing + training.

Lease vs buy. Lease $2,000-$5,500/mo per 1,000 sq ft suburban, $4,000-$9,000 metro. Many OD owners buy real estate via separate LLC + lease to PC.

2. Exam-lane equipment fundamentals

Chair-stand + delivery + slit lamp + lighting. $15-$25K per lane new (Marco/Reichert/Reichelt TRS-3100/5100/6100 gold standard; Topcon CV-5000; Nidek RT-6100). Refurb $7-$15K saves $8-$15K/lane.

Phoropter. $4-$12K manual (Reichert Ultramatic RX, Marco RT-700, Topcon VT-10) vs $8-$18K digital integrated (Marco TRS-5100, Topcon CV-5000PRO, Nidek RT-6100, Visionix VX55).

Slit lamp. $4-$12K (Haag-Streit BQ-900 gold at $10-$15K, Topcon SL-D $5-$10K, Marco/Reichert $4-$8K). Add digital imaging module $3-$8K for anterior segment photography + dry eye documentation.

Auto-refractor + keratometer. $7-$15K (Nidek ARK-1s, Topcon KR-800, Marco Equip ARK-510A, Reichert RK-700, Visionix VX120).

Non-contact tonometer. $3-$8K (Reichert 7CR, Topcon CT-1, Nidek NT-510). Or iCare TA01i rebound $2-$4K (handheld, pediatric-friendly).

3. Diagnostic imaging (the medical-OD enablers)

Retinal camera. $25-$130K range. Canon CR-2 $25-$40K entry non-mydriatic. Topcon TRC-NW8 $35-$55K. Optos California $90-$130K (ultra-widefield 200deg single capture, no dilation -- dominant upgrade, drives medical billing 92250 fundus photo ~$50 Medicare).

OCT. $40-$80K. Heidelberg Spectralis $60-$80K (gold standard, multimodal). Topcon Maestro2 $40-$55K. Zeiss Cirrus 6000 $45-$70K. Optovue iVue 80 $35-$50K. AI-augmented analysis (Notal Vision, RetinAI, Eyenuk) flags AMD + DR + glaucoma RNFL thinning. Highest-ROI medical-OD investment -- 92133 RNFL OCT ($45) + 92134 macular ($45).

Corneal topographer. $25-$45K. Medmont E300 $30-$45K (ortho-k + RGP fitting gold). Eaglet Eye ESP $25-$40K (scleral fitting). Oculus Pentacam $35-$55K (keratoconus + LASIK referral). Essential for myopia management ortho-k + specialty CL fitting.

Visual field. $20-$30K. Zeiss Humphrey HFA3 $22-$30K (gold standard, SITA Faster). Octopus 900 $25-$35K. Drives glaucoma billing 92083 ($60-$80).

Axial length biometer. $45-$70K. Zeiss IOLMaster 700 $55-$70K (gold, swept-source). Topcon Aladdin $35-$50K. Tomey OA-2000 $40-$55K. CRITICAL for myopia management -- axial length is the only direct measure of myopia progression + pathology risk. 2027 myopia protocol REQUIRES axial length every 6 months per IMI consensus.

4. Optical lab + frame inventory

Lab partnership. Most ODs outsource: Essilor Independent Labs (owns Varilux, Crizal, Transitions, Eyezen, Stellest), Walman Optical (employee-owned), IcareLabs, Hoya Vision Care, Younger Optics (Drivewear/NuPolar), Shamir Insight (Glacier+). Lab does surfacing + tinting + coating + edging + mounting; ships in 5-10 business days.

In-house edging (optional). $25-$60K finishing edger (Briot Accura, Santinelli LE-1200, Essilor Mr Blue) enables same-day stock-lens glasses. ROI debatable sub-$1.5M.

Frame inventory opening. $30-$80K for 300-800 frames. Margin: 3x retail markup standard. Mid-market designer (Coach, MK, Burberry, Calvin Klein -- via Marchon/Safilo/Luxottica) $80-$140 cost / $240-$420 retail. Premium (Tom Ford, Gucci, Prada -- Luxottica/Kering) $150-$280 cost / $450-$840. Independent boutique (Etnia Barcelona, Lafont, Anne et Valentin, Salt, Garrett Leight, Moscot, Lindberg) $130-$320 cost / $390-$960. Kids (Dilli Dalli, OGI) $40-$90 cost / $120-$270 for myopia volume.

CL inventory. 200-500 trial SKUs from CooperVision (MiSight, Biofinity, MyDay), J&J Vision (Acuvue Oasys 1-Day, Vita, Moist), Alcon (DAILIES TOTAL1, Air Optix), Bausch + Lomb (INFUSE, Biotrue, Ultra), specialty (X-Cel, Valley Contax, BostonSight SCLERAL). Direct-ship annual supply w/ rebates $75-$200/yr/patient.

5. PMS + AI imaging + supplies

PMS. $300-$1,500/mo: Compulink Advantage (legacy + cloud, broad OD-specific), RevolutionEHR (cloud, fastest-growing independent), Crystal PM, Eyefinity OfficeMate + ExamWriter (VSP-owned, deep VSP integration), Maximeyes by NextGen, My Vision Express, Acuity Logic (chain sublease), Uprise (VSP/Eyefinity newer cloud).

Patient comms + recall. Weave (PMS-integrated text + voice + reviews + payments, fastest-growing), Solutionreach (legacy), NexHealth, Doctible, 4Patient Care.

AI fundus/OCT analysis (NEW 2024-2027). $300-$2,000/mo: Eyenuk (FDA-cleared diabetic retinopathy), Notal Vision (AMD home monitoring), RetinAI (multi-pathology OCT), AEYE Health (FDA autonomous DR), Optomed Aurora AEYE (handheld + AI).

Supplies. Three dominant ophthalmic distributors: Lombart Instruments, Marco Ophthalmic, Veatch Ophthalmic. Frame distribution direct from Luxottica, Safilo, Marchon, Marcolin, Kering Eyewear, ClearVision Optical, Modern Optical. Annual consumables 3-lane practice $25-$55K.

6. SBA + eyecare-specific financing

Eyecare has built the second-strongest specialty-finance ecosystem after dental -- sub-2% historical default rate.

Typical 3-lane de novo 2026: lease $0 + TI $500-$875K + lane equipment $105-$225K + retinal camera + OCT + topographer + visual field + biometer $180-$355K + frame inventory $30-$80K + IT/PMS/signage $25-$45K + working capital $80-$200K = $350-$800K de novo or $600K-$1.5M (real estate purchase).

Acquisition financing: $400K-$1.2M (60-80% trailing collections) + 10-20% down + SBA 7(a) 75-90% + seller note 5-15% at 6-8% 5-7 yr + working capital reserve $40-$120K.

Eyecare-specific lenders: Live Oak Bank Eyecare Lending (top SBA), Bank of America Practice Solutions (largest non-SBA), First Citizens Practice Solutions (was Square 1), Provide.com (was Lendeavor, expanded to eyecare 2022), Huntington Practice Finance, US Bank Practice Finance, TD Bank Healthcare. Equipment leasing: Marco Financial, Topcon Financial, US Bank Equipment Finance, Western Equipment Finance, Essilor Instruments.

---

PART 3 -- OPERATIONS

1. Hiring

Associate OD. $130-$170K starting new-grad (BLS 2024 + AOA Career Survey). $160-$220K experienced 5+ yr + production bonus 18-22%. Highest-paying: Costco $150-$200K + benefits, MyEyeDr $140-$180K + production, large groups $150-$220K + partnership track.

Optician. $42-$60K licensed (~22 states require optician licensure -- CA/FL/NY/NJ/CT/MA/RI/HI/GA/KY/MD/etc.). ABO + NCLE certifications optional but increasingly required -- adds $3-$6/hr premium. Top opticians closing 70-85% optical capture earn $55-$85K + commission. THE most important non-OD hire -- drives 55-70% of practice gross.

Optometric technician. $18-$28/hr for pre-test + chair-side + diagnostic equipment operation. ABO/NCLE Optical Technician cert $0.50-$2/hr premium.

Optical sales. $16-$24/hr base + commission ($35-$50K base + $5-$25K commission). Commission: 4-8% of net optical sales OR tiered. Separate from licensed optician role -- handles frame selection + lens upgrade + insurance breakdown + financing + 2nd-pair offers. Best drive 30-50% revenue lift over untrained.

Front office. $16-$22/hr + insurance verification + scheduling + recall + collections. 2-4 per 3-4 lane practice. Outsource RCM optional (RevSync, Insight Practice Partners).

2. Vision insurance vs medical billing workflow

The single most consequential financial decision is payer mix -- which vision plans + medical insurance to credential with + how aggressively to bill medical.

Four major vision plans (each 60-120 day credentialing): VSP Vision Care (~80M lives, dominant US vision insurance -- owns Eyefinity OfficeMate + Marchon frames; ~30% market share). EyeMed (~70M, EssilorLuxottica-owned, ties to LensCrafters/Pearle/Target chains, often lowest-paying for independents). Spectera / UnitedHealthcare Vision (~25M, UHG-owned). Davis Vision / MetLife (~20M). Plus Versant (Superior), NVA, March Vision (Medicaid).

Vision plan write-off math. Allowed amounts write off 40-60% of UCR. Example: UCR progressive + premium AR $480; VSP Choice allowed $230 + member copay $60 = $290 reimbursement = 40% write-off. Frame UCR $300; VSP allowance $130 + 20% over-allowance copay = $164 = 45% write-off. Heavy vision-plan 18-28% net; light + medical-heavy 35-50%; FFS/concierge 40-55%.

The medical-OD billing transition. Vision codes 92002/92004/92012/92014 ($45-$95) bill under vision plans. Medical codes 99213/99214/99215 ($75-$170) bill under BCBS/Aetna/Cigna/UHC/Medicare with medical chief complaint -- "red eye, foreign body, blur with diabetes, headaches, sudden floaters, ptosis, double vision, dry eye". Add ancillaries: 92133 RNFL OCT ($45), 92134 macular OCT ($45), 92250 fundus photo ($50), 92083 visual field ($60-$80), 92020 gonioscopy ($25), 92015 refraction (patient-pay $50-$80 if non-covered). Diabetic eye exam G0117 ($53 Medicare) is bread-and-butter.

3. The S-T-O-P optical sale workflow

Optical capture is the optometry version of dental case acceptance. Patient finishes exam w/ Rx; optician has 5-15 min to convert to frame + lens + AR + photochromic + 2nd-pair before patient leaves to LensCrafters/Costco/Warby Parker/1-800-CONTACTS/EyeBuyDirect/Zenni. Top closes 70-85%; bottom 35-45%. 30-50 point gap = difference between $650K and $1.4M practice on same OD-hours.

> ### Key Stat > Per Review of Optometric Business + Vision Source + IDOC benchmarks, top decile reports optical capture 75-85% vs bottom quartile 30-40%; gap driven by S-T-O-P workflow: (S)elect frame based on face shape + lifestyle + Rx, (T)alk lens tech (high-index 1.67/1.74 thin Rx, polycarbonate kids/sports, Trivex rimless, occupational progressives), (O)ffer treatments (premium AR Crizal Sapphire/Sapphire HR, blue-blocker, photochromic Transitions Gen 8 / Drivewear), (P)osition pricing (insurance + financing CareCredit/Sunbit + 2nd-pair + annual CL supply). Bottom hands patient paper Rx + sticker.

4. Contact lens revenue + specialty CLs

CL annual supply is the recurring-revenue analog. Top practices convert 75-90% to annual supply (12-mo bulk + manufacturer rebate $75-$200 + direct-ship + auto-reorder). Daily disposables dominate -- Acuvue Oasys 1-Day with HydraLuxe (J&J, premium daily), DAILIES TOTAL1 (Alcon, water-gradient), MyDay (CooperVision, silicone hydrogel daily), Biotrue ONEday (B+L). Monthly silicone hydrogels -- Acuvue Vita, Air Optix HydraGlyde, Biofinity, Ultra.

Specialty CLs (the differentiation moat). Sclerals ($1,200-$3,500 fit + $400-$900 replacement) for keratoconus, post-LASIK ectasia, severe dry eye. Labs: BostonSight SCLERAL, Valley Contax, X-Cel Specialty, Visionary Optics, Essilor Custom Stable. Multifocal CLs (DAILIES TOTAL1 Multifocal, Ultra Multifocal, Biotrue) $80-$140 fit. Ortho-K ($1,500-$3,500 fit + $600-$1,200/yr replacement) -- Paragon CRT (CooperVision), Wave, Euclid Emerald.

5. The myopia management revenue lever

> ### Key Stat > Per CooperVision MiSight data + Brien Holden Vision Institute + International Myopia Institute + Review of Optometric Business: childhood myopia prevalence ~25% in US 2024, projected ~50% globally by 2050; high myopia (>-6.00) carries 5-10x lifetime risk of myopic maculopathy + retinal detachment + open-angle glaucoma per IMI consensus. Myopia management is a $4-$6B emerging specialty growing 25-40%/yr with FDA-approved CooperVision MiSight 1-day (only FDA-approved myopia control CL) + Essilor Stellest + Hoya MiYOSMART + Visioneering NaturalVue Multifocal + ortho-k + atropine 0.05% (Imprimis/Leiter's). Top myopia practices package $1,500-$3,500/yr per pediatric patient + 6-mo follow-up + axial length (IOLMaster 700) + parent education.

6. Dry eye disease center model

DED is the strategic patient-acquisition front door + a $300-$3,000/protocol revenue stream OUTSIDE vision insurance. Estimated 16-49M US adults suffer DED.

Diagnostics: TearLab Osmolarity ($35-$60 patient-pay, gold), InflammaDry (MMP-9 $30-$50), LipiScan/LipiView (J&J Vision meibography $50-$100), Schirmer test (basic), Oculus Keratograph 5M ($25-$45K tear meniscus + NIBUT + meibography all-in-one).

Treatment: IPL (Intense Pulsed Light) Lumenis OptiLight M22 ($75-$110K capital + $250-$400/session x 4-session = $1,000-$1,600/course). LipiFlow thermal pulsation (J&J, $80-$120K + $700-$1,200/treatment). iLux / TearCare (lower-capital). NULIDS at-home $200-$400. OmegaScan/EyePromise nutraceutical omega-3. Rx pharmacotherapy (Restasis, Cequa, Xiidra, Tyrvaya, Miebo, Eysuvis -- bill medical w/ prior auth).

7. Compliance: HIPAA + OSHA + state board + FTC + optician licensure

> ### Warning > HIPAA breach + state board complaint + dispensing without licensed optician (licensure states) + FTC Rx withholding = automatic civil penalty + potential license suspension.

HIPAA + HITECH -- annual Risk Assessment, BAAs every vendor (PMS, AI imaging, billing, IT, texting), encrypted email/storage, 60-day breach notification. Civil penalty $100-$50K per record (capped $1.5M/yr per category).

OSHA + Bloodborne. Disinfection of slit lamp + tonometer tip + trial lens + after dilation + IPL eye-safety. Annual training + sharps log.

State OD board + CE. Standard-of-care (missed glaucoma/retinal detachment/melanoma), billing fraud (G0117/fundus photo without indication), advertising, prescription release. CE renewal current.

Optician licensure in ~22 states (CA/FL/NY/NJ/CT/MA/etc.). Practice must employ licensed opticians OR OD personally dispenses. ABO + NCLE voluntary nationwide.

FTC Eyeglass Rule + Contact Lens Rule. Federal rule -- glasses Rx released to patient no charge after refraction. CL Rx released after fitting + verified 1 year. Cannot condition Rx release on optical purchase. Violation = FTC enforcement.

---

PART 4 -- GROWTH & EXIT

1. Marketing realities

Dominant 2027 OD channels: Google + Google Business Profile + Google Reviews + Healthgrades + ZocDoc + Facebook for myopia-management parent-targeted + postcard mail for new movers + dry eye as front door.

Reviews. Goal: 4.7+ stars x 100+ Google reviews. Asked at checkout via Weave/Solutionreach/NexHealth/Doctible. Negative response within 24 hrs, no PHI disclosure.

Healthgrades + ZocDoc drive 25-40% of new-patient appointments at urban/suburban practices. ZocDoc charges $40-$110/booked new patient.

Dry eye marketing as front door. Top-decile practices market DED screening as patient acquisition wedge -- converts to comprehensive exam + medical billing + IPL/LipiFlow packages.

Facebook for myopia management. Parent-targeted (4-12 yo children, parent age 30-50, HHI $75K+) for MiSight/Stellest/ortho-k. CAC $200-$500/child; LTV $4,000-$8,000/4-yr course.

Patient referrals = #1 acquisition channel mature -- 30-45% of new-patient volume. Refer-a-friend $25-$50 + experience excellence + automated review-request.

2. Scale model

Yr 0-3 solo $550K-$1.2M 22-35% net -> Yr 3-7 2-OD or 2nd location $1.5-$3M 18-30% -> Yr 7-12 multi-location 3-5 $3-$10M 16-26% -> Yr 12-20 regional 6-15 $10-$40M 14-22% -> Yr 20+ platform 15-100+ $30M-$500M+ -> IDSO exit.

Second-location decision triggers at 85%+ chair-time + strong associate-OD ready as managing doctor OR attractive adjacent acquisition. Stage 1->2 stall solved by clear associate-to-partner pathway OR IDSO-equivalent funding 2nd location.

3. IDSO-equivalent market

> ### Key Stat > Per Vision Monday + Review of Optometric Business + Provident Healthcare Partners eyecare M&A: eyecare IDSO partial-recap multiples 2024-2026 run 5-8x EBITDA for $250-$750K EBITDA, 6-9x for $750K-$1.5M EBITDA groups, 8-12x for $1.5M+ platforms. Owner sells 60-80% equity + retains 20-40% rolled into platform equity + second-bite at next recap in 3-7 yrs typically returns 2-3x on retained. Multiples expanded 1-2 turns 2020-2024 as IDSO competition intensified.

Deal structure typical. $1.2M collections + $300K EBITDA -> 6.5x EBITDA = $1.95M EV + IDSO buys 70% = $1.36M cash + owner retains 30% = $585K + 3-5 yr contract + clinical autonomy + branding. At next recap (3-5 yr) platform sells at 9-12x EBITDA = retained worth $1.0-$1.7M = 2-3x = total to owner $2.4-$3.1M vs traditional sale 0.65-0.85x collections = $780K-$1.0M one-time.

Best M&A advisory: Provident Healthcare Partners (eyecare-specific), Vision Monday Group, Cain Brothers, ROI Corp (was Edgewood), Eyecare Practice Transitions, Williams Group, Practice Concepts.

4. Vision Source / IDOC / PECAA affiliate routes

Vision Source (Essilor-owned since 2015, ~3,000+ ODs, $750/mo) -- buying group + Essilor lens 8-15% rebate + frame co-op + CL rebates + consulting. IDOC (~500 affiliates, ~$1,200/mo, Dave Brown CEO) -- heavier consulting + financial benchmarking + IDOC Connection conference. PECAA (~1,500+ aligned ODs) -- buying group + insurance leverage. Best for ODs who want to stay independent forever but capture chain-scale buying economics.

5. Exit options

(1) IDSO-equivalent partial-recap. Sell 60-80% to EyeCare Partners/MyEyeDr/Keplr/US Eye/VIP/Spectrum at 5-8x EBITDA + retain 20-40% + clinical autonomy + 3-5 yr contract + second-bite. Best for ODs 5-15 yrs from retirement seeking partial liquidity + reduced ops burden.

(2) Traditional sale to single buyer. Sell to another OD (often new-grad with SBA + eyecare-specific lender) at 60-80% of trailing 12-mo collections + working capital. Broker (Provident/ROI Corp/Eyecare Practice Transitions/Williams/Practice Concepts) + 6-18 mo timeline + seller note 5-15%. PacNW/Bay/NYC premium 75-90%; rural Midwest 50-65%.

(3) Merge with peer. Two adjacent solo ODs merge into 2-OD group sharing facility + equipment + insurance.

(4) Associate-to-partner buyout. Owner sells to long-time associate over 3-5 yr staged. Yr 1-2 associate buys 20-30% at 75-80% of collections-based valuation.

(5) Lifestyle-OD / multi-generational independent. Stay 1-OD or 2-OD at $700K-$1.5M, take home $180-$320K, work 32-38 hrs/week. Dominant choice for ~50-60% of independent ODs per AOA.

6. The chain threat + independent moats

Chains compete on price + insurance volume + convenience. Independents counter with clinical depth + relationships + specialty:

• Myopia management -- chains rarely build (requires biometer + topo + dedicated CE + parent consultation)
• Dry eye disease center -- chains don't invest in $200-$310K IPL/LipiFlow capital
• Specialty CLs -- sclerals + ortho-k + custom multifocals require fitting skill + topo + lab relationships
• Neuro-optometry / post-concussion -- emerging specialty (neurolens prism, vision therapy TBI, sports vision)
• Premium relationship care -- 45-min comprehensive exams + same-OD continuity; chains run 15-20 min slots
• Medical-OD chronic disease -- diabetic + glaucoma + dry eye + AMD at 2-3x vision-plan reimbursement

The 2027 surviving independent optometry practice is built deliberately for one of five end-states: (a) IDSO-equivalent partial-recap at 5-8x EBITDA + retained equity second-bite, (b) traditional sale at 60-85% collections, (c) merge with adjacent peer, (d) phased associate/family succession with real-estate retention, OR (e) multi-generational lifestyle independent. Practices drifting without exit clarity get under-valued OR forced into rushed sale to whichever chain/IDSO appears first.

The Operating Journey: From Solo Lane Cold-Start To Multi-Location + IDSO Exit

×

CRO SYNDICATE

SPONSORED

Kory WhiteFractional CRO · 25 yrs · $0→$200M

Hire a Fractional CRO

Need a fractional Chief Revenue Officer?

Chief Revenue OfficerRevenue LeaderVP of SalesSales Leader

CRO Syndicate connects you with vetted fractional & interim revenue leaders — nationwide and across Maryland & DC.

Book a Call →

Kory White LinkedIn →CRO Syndicate →

Related on PULSE

• [How Do I Budget an Optometry Office With an On-Site Lab?](/knowledge/q13820)
• [How do you start a physical therapy practice in 2027?](/knowledge/q9687)
• [How do you start a dental practice in 2027?](/knowledge/q9683)
• [How do you start a chiropractic practice in 2027?](/knowledge/q9685)
• [How do you start a pediatric dental practice in 2027?](/knowledge/q9668)
• [How do you start a direct primary care (DPC / concierge medicine) practice in 2027?](/knowledge/q9660)

FAQ

What is the minimum capital needed to start an optometry practice in 2027? For a solo-OD independent model, you’ll need roughly $250,000 to $600,000 in startup capital. This covers leasehold improvements, exam lane equipment, frame inventory, and working capital for the first 6–12 months. A corporate-affiliated sublease can reduce that to $100,000–$250,000, but you’ll share revenue.

How long does it take to break even on a new practice? Most independent optometry practices reach break-even within 12 to 24 months, depending on location, patient volume, and payer mix. Those in high-traffic retail settings or with strong optical capture (60%+ of exam patients buying glasses) can break even sooner, sometimes by month 9.

Which business model offers the highest owner-OD income? Solo-OD independent practices typically yield the highest net income per owner, ranging from $135,000 to $420,000 annually, but come with the greatest risk and workload. Multi-OD groups spread overhead, so each owner may net $150,000–$300,000, while corporate-affiliated ODs often earn $120,000–$180,000 as W-2 employees.

How important is optical capture for profitability? Optical capture—the percentage of exam patients who purchase glasses or contacts from your practice—is critical. Independent practices need at least 50–65% capture to be profitable, with top performers hitting 75%+. Lower capture rates force you to rely heavily on exam fees and medical billing, which often have lower margins.

What are the biggest startup mistakes to avoid in 2027? Common pitfalls include underestimating lease costs (especially in retail centers), over-ordering frame inventory (aim for 600–1,000 frames, not 2,000+), and neglecting payer contracts—Medicare and major commercial plans can take 90+ days to reimburse. Also, failing to budget for digital marketing and online scheduling can slow patient growth.

Do I need to join an affiliate network like Vision Source or IDOC? It’s optional but can help. Affiliate networks provide group purchasing discounts on frames and lenses, marketing support, and payer contract leverage, often for $750–$1,200 per month. However, they take a percentage of optical revenue (typically 1–3%) and may limit your brand independence. Many successful solo ODs operate without them.

Sources

1. **American Optometric Association (AOA)** -- Annual Practice Survey + OD supply + benchmarks
2. **ARBO (Association of Regulatory Boards of Optometry)** -- state licensure + NBEO
3. **ASCO (Association of Schools and Colleges of Optometry)** -- ~23 ACOE-accredited schools + grad placement + debt
4. **NBEO (National Board of Examiners in Optometry)** -- Parts I/II/III
5. **AAO (American Academy of Optometry)** -- annual meeting + fellowship + research
6. **BLS Occupational Outlook 2024 -- Optometrists** -- supply + wages + employment
7. **Vision Council** -- US optical retail $50B+
8. **Review of Optometric Business (RoB)** -- practice benchmarks + chain market share
9. **Review of Optometry Magazine** -- clinical + practice CE
10. **Modern Optometry Magazine** -- practice mgmt + clinical
11. **Vision Monday** -- optical retail + chain + M&A news
12. **Brien Holden Vision Institute** -- global myopia prevalence research
13. **International Myopia Institute (IMI)** -- myopia mgmt consensus + axial length protocols
14. **EssilorLuxottica (NYSE: EL)** -- Francesco Milleri Chairman + Andrea Guerra CEO + LensCrafters+Pearle+Target Optical+Sunglass Hut+EyeMed+Essilor
15. **LensCrafters** -- ~840 stores EssilorLuxottica
16. **Pearle Vision** -- ~500 franchise + corporate
17. **National Vision Inc (NASDAQ: EYE)** -- Reade Fahs CEO + ~1,400 stores + America's Best ~900 + Eyeglass World ~125 + Walmart Vision sublease + Fred Meyer
18. **America's Best Contacts & Eyeglasses** -- ~900 stores
19. **MyEyeDr** -- KKR-backed 2019 + Sue Downes CEO + ~860 offices fastest-growing roll-up
20. **Walmart Vision Centers** -- ~3,000+ stores sublease ODs
21. **Costco Optical** -- ~580+ warehouses + employed ODs $130-$180K
22. **Warby Parker (NYSE: WRBY)** -- Neil Blumenthal + Dave Gilboa + ~270 stores + ecommerce
23. **Vision Source** -- Steven Eiss + Essilor-owned 2015 + ~3,000+ affiliated ODs + $750/mo
24. **IDOC** -- Dave Brown CEO + ~500 affiliate + ~$1,200/mo + IDOC Connection
25. **PECAA** -- ~1,500+ aligned ODs + buying group + advisory
26. **EyeCare Partners** -- Partners Group + FFL Partners + ~700+ OD+MD largest
27. **EyeSouth Partners** -- Shore Capital + ~300+ ophthalmology-heavy
28. **Keplr Vision** -- Greenbriar Equity + ~110+ practices independent-friendly
29. **US Eye** -- Kuvera + Aldine + ~75+ OD+MD
30. **Vision Innovation Partners (VIP)** -- Centre Lane Partners + ~80+
31. **Spectrum Vision Partners** -- PE-backed Northeast OD+MD
32. **VSP Vision Care** -- Michael Guyette CEO + ~80M lives largest US vision insurance + Eyefinity OfficeMate + Marchon + ~30% share
33. **EyeMed Vision Care** -- Lukas Ruecker CEO + ~70M + EssilorLuxottica-owned
34. **Spectera / UnitedHealthcare Vision** -- ~25M UHG
35. **Davis Vision / MetLife Vision** -- ~20M
36. **Versant Health (Superior+Davis)** -- merged vision plan
37. **CooperVision (Cooper Companies NYSE: COO)** -- MiSight 1-day FDA + Biofinity + MyDay + Paragon CRT ortho-k
38. **Johnson & Johnson Vision** -- Acuvue Oasys 1-Day HydraLuxe + Vita + Moist + LipiFlow + LipiScan
39. **Alcon (NYSE: ALC)** -- DAILIES TOTAL1 + Air Optix HydraGlyde + Precision1
40. **Bausch + Lomb (NYSE: BLCO)** -- INFUSE + Biotrue ONEday + Ultra
41. **Hoya Vision Care** -- Hoya Free-Form + MiYOSMART myopia + Recharge AR
42. **Essilor (EssilorLuxottica)** -- Varilux + Crizal + Transitions + Eyezen + Stellest myopia + Independent Labs
43. **Younger Optics** -- US lens lab + Drivewear + NuPolar
44. **Shamir Insight** -- Autograph III + Glacier+ AR + Computer + Blue Zero
45. **Walman Optical** -- employee-owned wholesale lab
46. **IcareLabs** -- FL independent wholesale lab
47. **Marchon Eyewear** -- Calvin Klein + Lacoste + Nike + Ferragamo distribution
48. **Safilo Group** -- Carrera + Hugo Boss + Jimmy Choo + Marc Jacobs
49. **Marcolin** -- Tom Ford + Guess + Bally + Tod's distribution
50. **Kering Eyewear** -- Gucci + Saint Laurent + Cartier + Balenciaga
51. **Heidelberg Engineering** -- Spectralis OCT gold standard multimodal
52. **Carl Zeiss Meditec (XETRA: AFX)** -- Humphrey HFA3 + Cirrus 6000 OCT + IOLMaster 700
53. **Topcon Healthcare** -- TRC-NW8 + Maestro2 + CT-1 + CV-5000 + KR-800 + Aladdin
54. **Optos (Nikon)** -- California ultra-widefield 200deg + Daytona
55. **Optovue (Visionix)** -- iVue 80 OCT + AngioVue
56. **Nidek Inc** -- ARK-1s + NT-510 + RT-6100 + OPD-Scan
57. **Marco Ophthalmic** -- Reichert acquired + TRS-3100/5100/6100 + Equip ARK-510A
58. **Reichert Technologies** -- 7CR NCT + Ultramatic RX phoropter
59. **Haag-Streit** -- BQ-900 slit lamp gold + Octopus 900 visual field
60. **iCare USA** -- TA01i rebound tonometer pediatric-friendly
61. **Medmont International** -- E300 corneal topographer ortho-k + scleral
62. **Eaglet Eye** -- ESP scleral lens fitting profilometry
63. **Oculus** -- Pentacam Scheimpflug + Keratograph 5M dry eye
64. **Tomey USA** -- OA-2000 axial length biometer
65. **Canon Medical (USA)** -- CR-2/CR-2 Plus non-mydriatic retinal cameras
66. **Lombart Instruments** -- broadest optometry equipment distribution
67. **TearLab Corporation** -- osmolarity diagnostic gold
68. Quidel InflammaDry -- MMP-9 inflammation strip.
69. **Lumenis** -- OptiLight M22 IPL FDA dry eye
70. **NuLids System** -- at-home dry eye device
71. EyePromise / OmegaScan -- omega-3 nutraceutical.
72. AbbVie (NYSE: ABBV) -- Restasis + Eysuvis + Allergan eye care.
73. Sun Pharma -- Cequa cyclosporine.
74. Viatris -- Tyrvaya nasal spray.
75. **Bausch + Lomb -- Miebo** -- perfluorohexyloctane
76. **Eyenuk** -- FDA-cleared diabetic retinopathy AI EyeArt
77. **Notal Vision** -- ForeseeHome AMD home monitoring
78. **RetinAI** -- multi-pathology OCT AI
79. **AEYE Health** -- FDA-cleared autonomous DR
80. **Compulink** -- Advantage PMS legacy + cloud broad OD
81. **RevolutionEHR** -- cloud OD-specific PMS fastest-growing
82. **Crystal PM** -- independent OD-focused PMS
83. **Eyefinity OfficeMate + ExamWriter** -- VSP-owned deep VSP integration
84. Maximeyes by NextGen / My Vision Express / Acuity Logic / Uprise -- additional PMS options.
85. **Weave** -- patient comms text+voice+reviews fastest-growing eyecare
86. Solutionreach / NexHealth / Doctible / 4Patient Care -- recall + reactivation.
87. **BostonSight SCLERAL** -- scleral lens lab gold
88. Valley Contax / X-Cel Specialty / Visionary Optics / Essilor Custom Stable -- scleral + specialty CL labs.
89. **Visioneering Technologies** -- NaturalVue Multifocal myopia control
90. **Treehouse Eyes** -- myopia management franchise
91. Imprimis Pharmaceuticals / Pacific Compounding / Leiter's Pharmacy -- compounded atropine 0.05%.
92. **CareCredit (Synchrony NYSE: SYF)** -- dominant healthcare financing
93. Sunbit / Cherry / Alphaeon Credit / LendingPoint / Proceed Finance -- patient financing.
94. **Live Oak Bank Eyecare Lending** -- top SBA eyecare
95. **Bank of America Practice Solutions** -- largest non-SBA practice financier eyecare
96. First Citizens Practice Solutions -- was Square 1 strong eyecare book.
97. **Provide.com** -- was Lendeavor + expanded to eyecare 2022
98. Huntington Practice Finance / US Bank Practice Finance / TD Bank Healthcare -- additional eyecare lenders.
99. Marco Financial / Topcon Financial / US Bank Equipment Finance / Essilor Instruments -- equipment leasing.
100. Provident Healthcare Partners -- eyecare-specific M&A advisory + IDSO research.
101. ROI Corp (was Edgewood) -- eyecare practice transitions advisory.
102. Eyecare Practice Transitions / Williams Group / Practice Concepts -- practice broker advisory.
103. **FTC Eyeglass Rule** -- Rx released after refraction no charge
104. **FTC Contact Lens Rule** -- CL Rx released after fitting + 1-yr verification
105. HHS OCR HIPAA Privacy + Security + Breach Notification. https://www.hhs.gov/ocr
106. OSHA Bloodborne Pathogens 29 CFR 1910.1030. https://www.osha.gov/bloodborne-pathogens

Numbers & Benchmarks

1. Industry size & OD supply 2024-2026

2. Chain consolidation trajectory (RoB)

3. Top chains + IDSO equivalents

4. Capital + practice launch 2026

5. Exam-lane equipment cost by tier

6. Vision plan write-off vs medical-OD net

7. Myopia management ARR per pediatric (4-yr course)

8. Dry eye disease protocol pricing

9. OD salary by setting (AOA + BLS 2024)

10. IDSO vs traditional sale multiples eyecare 2024-2026

11. Exam volume per OD-day benchmarks (RoB + IDOC)

Counter-Case: When An Optometry Practice Is A Bad Bet

A serious founder must stress-test against conditions that make 2027 optometry brutal:

(1) Chain saturation kills exam volume. If LensCrafters + America's Best + MyEyeDr + Walmart + Costco all sit within 2 miles, CAC is 2-3x higher + capture lags 30-50%. Scout zip-level chain density before signing. Independents thrive in zips with 1-2 chains max + suburban density 25K+ HH + HHI $75K+ + pediatric or 45+ retiree demographics.

(2) Taking VSP at full panel and bleeding optical margin 40-60%. VSP ~30% market share is hard to skip but reflexive credentialing w/ VSP + EyeMed + Spectera + Davis + Versant + March compresses optical net to 18-25%. The fix: open w/ VSP + 1-2 zip-relevant plans MAX + aggressive medical-OD billing + dry eye + specialty CL + myopia mgmt OUT-of-vision-plan. Drop EyeMed (lowest-paying, ties to chains) by year 2.

(3) Under-investing in OCT + topographer + biometer. Independents opening 2027 without OCT ($40-$80K) + topographer ($25-$45K) + axial length biometer ($45-$70K) cannot bill 92133/92134 medical OCT, cannot fit ortho-k/sclerals, cannot measure axial length for myopia per IMI. Result: forced into vision-plan-only competing with chains on price = loses. 2027 minimum: OCT + topographer + biometer + retinal camera = $200-$355K.

(4) Ignoring optical S-T-O-P and missing 30-50% of revenue. Optical = 55-70% of independent OD gross. Top closes 75-85% via Select-Talk-Offer-Position; bottom 30-40% hands patient paper Rx + sticker. Gap on same OD-hours = $500-$700K/yr on $1M practice. Owners blame "patients shopping online" when actual cause is no optician training + no S-T-O-P + no financing + no 2nd-pair.

(5) Staffing wrong mix. Common mistake: 2 part-time licensed opticians at $42-$60K. Better: 1 licensed optician (legal cover + complex Rx) + 1-2 dedicated optical sales ($16-$24/hr + 4-8% commission, trained on S-T-O-P) + 2 cross-trained techs ($18-$28/hr pre-test + scribe). Optical sales role drives 30-50% revenue lift.

(6) Failing to credential medical carriers. New ODs credential vision plans only, skipping BCBS/Aetna/Cigna/UHC/Medicare = cannot bill 99213-99215 + 92133 + 92134 + 92250 + 92083 + G0117 under medical. Medical credentialing 60-120 days per carrier -- start 4-6 months pre-opening. Heavy-medical 35-50% net vs heavy-vision-plan 18-28%.

(7) Ortho-K without proper training = liability + microbial keratitis risk. Ortho-K is $4-$8K LTV but carries 1:2,000-1:10,000 MK risk per literature. ODs without training = malpractice + state board complaint. The fix: Vision By Design + IAOMC + Paragon CRT certification + ~100 hr CE + first 20 fits under mentor + meticulous hygiene education + 1-week + 1-month + quarterly follow-ups.

(8) Over-leveraging de novo = 18-30 mo cash burn. Cold-start $350-$800K capital + $40-$75K/mo overhead + 18-30 mo ramp = $500K-$1.4M total cash before profitability. Family/spousal bridge typical. Acquisition (0-6 mo ramp) preferable for risk-averse; SBA 7(a) $400K-$1.2M at 60-80% collections + reserve $40-$120K.

(9) Drifting without exit clarity. 50s-60s without exit plan = suboptimal valuation -- rushed sale 0.55-0.70x OR forced IDSO uncompetitive multiple OR sold to local MyEyeDr at chain valuation. Plan 5-10 yr in advance: IDSO 5-8x EBITDA + second-bite OR mini-multi-location 6-9x OR phased associate/family OR lifestyle independent.

(10) Losing your lead optician or associate OD mid-year. 1-OD + 1-lead-optician practices are fragile. Lead optician (S-T-O-P closer) leaves = optical capture collapses 30-50% for 3-6 months. Associate OD leaves = exam volume cliffs immediately. Fix: 2 opticians minimum + above-market wage + commission + retention bonuses; associate OD vesting equity over 3-5 yr.

Honest verdict. Viable IF you (a) commit to S-T-O-P optical capture as #1 priority Day 1 -- licensed optician + trained optical sales + Select-Talk-Offer-Position + 2nd-pair + financing; (b) transition aggressively to medical-OD billing -- credential BCBS/Aetna/Cigna/UHC/Medicare + bill 99213-99215 + 92133/92134/92250/92083/G0117 + drop EyeMed year 2; (c) build myopia management as differentiating specialty -- biometer + ortho-k or MiSight + Stellest + atropine + pediatric marketing + $1,500-$3,500/yr packages; (d) build dry eye center as front door -- TearLab + LipiScan + optionally IPL OptiLight + $300-$3,000 protocol packages; (e) invest in diagnostic imaging at startup -- OCT + topographer + biometer + retinal camera + AI = 2027 minimum; (f) maintain HIPAA + OSHA + state OD board + optician licensure + FTC compliance documented; (g) track optical capture + medical-vs-vision mix + recall + show + production/OD-hour + myopia LTV; (h) understand chain/IDSO market early -- IDSO 5-8x EBITDA + second-bite OR mini-multi-location 6-9x OR phased family/associate OR lifestyle independent; (i) size working capital correctly for 18-30 mo de novo or 0-6 mo acquisition + spousal bridge. Otherwise 2027 economics grind toward EssilorLuxottica + MyEyeDr + National Vision + Walmart + Warby Parker chain compression + vision-plan write-off bleed + S-T-O-P-workflow gap.

Related Pulse Entries

• [[q9683]] -- Dental practice (DSO consolidation + hygienist recruiting + case acceptance parallel)
• [[q9682]] -- Auto repair shop (state-licensed + tech recruiting parallel)
• [[q9681]] -- Real estate brokerage (state-licensed + recruiting parallel)
• [[q9680]] -- Funeral home (community-relationship parallel)
• [[q9679]] -- Bookkeeping firm (PE roll-up parallel)

Recently Added — Related

• [How do you start a physical therapy practice in 2027?](/knowledge/q9687)
• [How do you start an urgent care clinic in 2027?](/knowledge/q9686)

People also search for: start an optometry practice · how to start an optometry practice · start an optometry practice guide